Details of the Drug

General Information of Drug (ID: DM30SGU)

Drug Name
Simvastatin
Synonyms
Cholestat; Coledis; Colemin; Corolin; Denan; Labistatin; Lipex; Lipovas; Lodales; Medipo; Nivelipol; Pantok; Rendapid; Simovil; Simvastatina; Simvastatine; Simvastatinum; Sinvacor; Sivastin; Synvinolin; Vasotenal; Zocor; Zocord; Simvast CR; Simvastatina [Spanish]; Simvastatine [French]; Simvastatinum [Latin]; MK 0733; MK 733; MK733; TNP00259; DRG-0320; KS-1113; L 644128-000U; MK-0733; MK-733; Simcard (TN); Simlup (TN); Simvacor (TN); Simvastatin & Primycin; Simvastatin, Compactin; Zocor (TN); Simvastatin [USAN:INN:BAN]; Simvastatin (JAN/USP/INN); Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
Indication
Disease Entry ICD 11 Status REF
Arteriosclerosis BD40 Approved [1]
Atherosclerosis BD40 Approved [1]
Coronary heart disease BA80.Z Approved [1]
Cystic fibrosis CA25 Approved [1]
Depression 6A70-6A7Z Approved [1]
Hypercholesterolaemia 5C80.0 Approved [2]
Hyperlipidemia 5C80.Z Approved [1]
Hyperlipidemia, familial combined, LPL related N.A. Approved [1]
Hypertriglyceridemia 5C80.1 Approved [1]
Pneumonia CA40 Approved [1]
Primary hypercholesterolemia 5C80.00 Approved [1]
Prostate carcinoma N.A. Approved [1]
Rhinitis FA20 Approved [1]
Type-1/2 diabetes 5A10-5A11 Approved [1]
Stroke 8B20 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticholesteremic Agents
Affected Organisms
Humans and other mammals
ATC Code
C10AA01: Simvastatin
C10AA: HMG CoA reductase inhibitors
C10A: LIPID MODIFYING AGENTS, PLAIN
C10: LIPID MODIFYING AGENTS
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 418.6
Logarithm of the Partition Coefficient (xlogp) 4.7
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.3-2.4 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Elimination
13% of the dose was excreted in urine and 60% in feces []
Half-life
The concentration or amount of drug in body reduced by one-half in 4.85 hours [3]
Metabolism
The drug is metabolized via a combination of spontaneous chemical conversion and enzyme-mediated hydrolysis by nonspecific carboxyesterases in the intestinal wall, liver, and plasma [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.3652 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.03 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Acute myocardial infarction Not Available MMP3 OTGBI74Z [7]
Arteriosclerosis Not Available CES1 OT9L0LR8 [7]
Cardiovascular disorder rs20455 KIF6 OTDH3MR4 [8]
Chemical Identifiers
Formula
C25H38O5
IUPAC Name
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
Canonical SMILES
CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
InChI
InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
InChIKey
RYMZZMVNJRMUDD-HGQWONQESA-N
Cross-matching ID
PubChem CID
54454
ChEBI ID
CHEBI:9150
CAS Number
79902-63-9
UNII
AGG2FN16EV
DrugBank ID
DB00641
TTD ID
D0H0ND
VARIDT ID
DR00435
INTEDE ID
DR1485
ACDINA ID
D00625
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [11]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [13]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [14]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [15]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [15]
Cytochrome P450 3A5 (CYP3A5)
Main DME 		DEIBDNY CP3A5_HUMAN Substrate [16]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [17]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [15]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [15]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (PLCG2) OTGVC9MY PLCG2_HUMAN Gene/Protein Processing [18]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Drug Response [19]
5-hydroxytryptamine receptor 3B (HTR3B) OTMGIYRE 5HT3B_HUMAN Drug Response [20]
5-hydroxytryptamine receptor 7 (HTR7) OT44DEWB 5HT7R_HUMAN Drug Response [20]
7-dehydrocholesterol reductase (DHCR7) OTLILBUI DHCR7_HUMAN Gene/Protein Processing [21]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Gene/Protein Processing [22]
Advanced glycosylation end product-specific receptor (AGER) OTPY0IH7 RAGE_HUMAN Gene/Protein Processing [23]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) OTAYZZE6 AL3A1_HUMAN Gene/Protein Processing [18]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Gene/Protein Processing [18]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Gene/Protein Processing [24]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Arteriosclerosis
ICD Disease Classification BD40
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
HMG-CoA reductase (HMGCR) DTT HMGCR 1.01E-05 0.65 1.53
P-glycoprotein 1 (ABCB1) DTP P-GP 3.29E-14 -7.08E-01 -1.99E+00
Breast cancer resistance protein (ABCG2) DTP BCRP 2.28E-08 -3.66E-01 -8.07E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 3.27E-01 -5.78E-02 -3.84E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 2.00E-01 5.79E-02 3.00E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.47E-02 -1.13E-01 -1.13E+00
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.65E-02 -8.90E-02 -5.58E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 4.03E-02 -1.19E-01 -5.11E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.05E-04 -1.51E-01 -8.87E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 3.24E-05 -3.48E-01 -1.34E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 120 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 3.2246 6.0735 2.7063 14.0213
MEC1 CTRP2 4.8509 7.6815 3.5614 6.6174
SU-DHL-1 CTRP2 -0.0222 1.3936 -0.0227 33.7558
NALM-6 CTRP2 1.1349 3.5571 1.0731 26.2542
NCI-H929 CTRP2 1.3627 3.1374 1.3459 24.5842
DEL CTRP2 1.4097 2.5358 1.4089 24.2176
P12-Ichikawa CTRP2 1.413 4.0419 1.3032 24.5662
KE-37 CTRP2 1.541 4.9131 1.256 24.3278
MV4-11 CTRP2 1.8144 3.9501 1.7467 21.748
EM-2 CTRP2 1.8447 3.8628 1.7899 21.5021
RPMI-8402 CTRP2 2.0309 4.8744 1.8005 20.8773
JVM-3 CTRP2 2.0887 4.46 1.9575 20.1414
THP-1 CTRP2; CTRP1 2.2693 4.4513 2.1563 18.9535
Ki-JK CTRP2 2.3313 4.2831 2.2513 18.3474
KMS-34 CTRP2 2.3623 4.3578 2.2721 18.1764
KMS-11 CTRP2; CTRP1 2.4074 4.7564 2.2418 18.2199
NB4 CTRP2 2.4241 3.0409 2.424 17.4572
Reh CTRP2 2.4609 4.2941 2.3887 17.4573
JVM-2 CTRP2 2.4699 6.0759 1.8983 19.215
MOLM-13 CTRP2 2.5129 5.016 2.2894 17.6461
L-540 CTRP2 2.5231 4.2362 2.464 16.9977
KMS-27 CTRP2 2.5879 5.8922 2.0921 18.1501
SR CTRP2 2.6011 3.877 2.584 16.3349
WSU-DLCL2 CTRP2; CTRP1 2.7957 3.6334 2.7937 15.0698
HD-MY-Z CTRP2 2.7995 5.8834 2.3232 16.6753
KE-97 CTRP2; CTRP1 2.825 5.3797 2.5264 15.9255
MOLT-16 CTRP2 2.8376 4.7465 2.7104 15.1414
Jurkat CTRP2 2.8456 5.892 2.3697 16.3683
Karpas-299 CTRP2 2.8469 5.0409 2.6471 15.3388
A3/Kawakami CTRP2 2.8747 4.7622 2.7472 14.8953
SKM-1 CTRP2; CTRP1 2.8886 4.2391 2.8536 14.5627
ALL-SIL CTRP2 2.9114 4.8959 2.7554 14.7524
A4/Fukuda CTRP2 2.9637 6.1927 2.3822 15.988
EHEB CTRP2 2.9803 6.4448 2.2993 16.2602
BL-70 CTRP2; CTRP1 3.0136 4.6493 2.9238 13.9204
RCH-ACV CTRP2 3.0546 5.4886 2.7371 14.3892
PF-382 CTRP2 3.1207 6.1265 2.575 14.813
KM-H2 CTRP2 3.1841 5.0875 3.0023 13.0306
HEL CTRP2 3.191 5.3426 2.9331 13.2628
SUP-T11 CTRP2 3.2725 5.0244 3.1161 12.3511
MOLM-6 CTRP2 3.3384 5.7663 2.9454 12.7907
HT CTRP2; CTRP1 3.4328 5.0371 3.2902 11.3206
Mono-Mac-1 CTRP2 3.4755 7.3389 2.4231 14.4694
MOLP-8 CTRP2 3.5664 6.0212 3.0893 11.6041
OCI-AML-2 CTRP2 3.6975 5.1467 3.5453 9.5095
F-36P CTRP2 3.7043 12.6091 0.0945 22.6359
RPMI-8226 CTRP2; CTRP1 3.7281 5.9841 3.28 10.5102
Peer CTRP2 3.7632 6.701 3.0019 11.4273
HDLM-2 CTRP2 3.8109 8.4162 2.2456 14.3643
KMS-18 CTRP2 3.9561 7.2267 2.9523 11.1464
SU-DHL-10 CTRP2 3.9601 5.0366 3.8632 7.5621
SU-DHL-8 CTRP2 3.9719 5.6667 3.6602 8.2875
P31/FUJ CTRP2 4.0952 7.2849 3.0602 10.3726
SU-DHL-4 CTRP2; CTRP1 4.1109 6.8477 3.2892 9.4871
Ku812 CTRP2; CTRP1 4.167 6.2868 3.6034 8.0816
MOLM-16 CTRP2; CTRP1 4.213 6.1376 3.7171 7.511
KMS-28BM CTRP2 4.239 9.1926 2.2661 13.3041
KMS-26 CTRP2 4.2963 6.5902 3.5848 7.7501
MC116 CTRP2; CTRP1 4.2977 5.2062 4.1838 5.4714
GDM-1 CTRP2; CTRP1 4.3288 11.8435 1.0405 17.9913
NU-DUL-1 CTRP2; CTRP1 4.3296 6.2626 3.7775 6.9747
U-937 CTRP2; CTRP1 4.3839 6.5918 3.6765 7.2525
NCO2 CTRP2 4.3887 7.8769 3.0504 9.738
SU-DHL-5 CTRP1 4.4265 6.2055 3.9001 13.3907
MM1.S CTRP2 4.4861 7.6779 2.6127 5.843
L-363 CTRP2 4.4869 6.2064 3.9519 5.7949
SUP-T1 CTRP2 4.703 10.2143 2.1697 12.7105
KMS-12-BM CTRP2 4.7631 6.2864 4.1758 4.2328
RS4;11 CTRP2 4.7698 8.0252 3.3194 7.7984
KCL-22 CTRP2 4.7819 7.6501 3.5168 6.9462
P3HR-1 CTRP2; CTRP1 4.7859 6.5828 4.0589 4.7569
TALL-1 [Human adult T-ALL] CTRP2 4.8022 10.2917 2.2163 12.3184
BV-173 CTRP2 4.9206 6.9069 4.0081 4.601
HEL 92.1.7 CTRP2 4.9297 7.0904 3.9243 4.9342
MHH-CALL-4 CTRP2 4.9319 6.8271 4.0576 4.3703
SIG-M5 CTRP2 4.9352 5.7024 4.6205 2.0046
HuNS1 CTRP2 4.9937 6.1982 4.4248 2.704
KMS-21-BM CTRP2 4.996 7.1462 3.9529 4.6819
JURL-MK1 CTRP2 5.0236 7.4201 3.8391 5.1065
KHM-1B CTRP2 5.0399 9.3946 2.8655 9.1606
CML-T1 CTRP2 5.0419 7.3701 3.8795 4.9015
ME1 CTRP2 5.0931 8.0861 3.5639 6.1293
Raji CTRP2 5.1224 7.466 3.8979 4.6705
PL21 CTRP2; CTRP1 5.1483 7.8559 3.7341 5.393
OCI-AML-3 CTRP1 5.1507 7.6691 3.8294 10.6739
MHH-CALL-3 CTRP2 5.1608 8.2197 3.5527 6.0488
HPB-ALL CTRP2 5.2557 7.6374 3.9195 4.336
NOMO-1 CTRP2; CTRP1 5.3027 10.6618 2.4579 10.4304
K-562 CTRP2 5.3137 6.9248 4.3181 2.5707
HL-60 CTRP2 5.3522 9.0801 3.277 6.8546
MOLT-13 CTRP2 5.4234 9.1253 3.3106 6.587
NU-DHL-1 CTRP2 5.4636 7.4207 4.1849 2.8796
SU-DHL-6 CTRP2 5.5421 9.1068 3.4116 5.9599
KO52 CTRP2 5.5827 7.7693 4.1003 3.042
SK-MM-2 CTRP2 5.6099 7.4027 4.2967 2.2042
OCI-Ly10 CTRP1 5.697 13.8471 1.1845 26.0061
HuT 78 CTRP2 5.7063 7.9755 4.087 2.9119
AML-193 CTRP2 5.7272 7.8836 4.1456 2.6455
JJN-3 CTRP2 5.8023 8.536 3.8827 3.5995
LAMA-84 CTRP2 5.8684 8.5361 3.9284 3.3188
Ri-1 CTRP2 5.9277 10.4571 3.0343 6.8834
MOLP-2 CTRP2 5.943 11.1227 2.7178 8.1576
OCI-M1 CTRP2 5.9625 7.6901 4.3857 1.4187
KMS-20 CTRP2 5.9704 10.3748 3.106 6.5203
M-07e CTRP2 6.1976 19.4584 -1.2255 21.5405
LP-1 CTRP1 6.4622 8.0596 4.504 1.4073
DND-41 CTRP2 6.5187 12.2044 2.6063 7.6991
EJM CTRP1 6.559 8.3015 4.4515 1.5914
Karpas-620 CTRP2 6.5917 8.3772 4.4227 0.7518
KYO-1 CTRP2 6.66 8.1949 4.5264 0.4393
SEM CTRP2 6.893 8.1602 4.6331 0.1527
AMO1 CTRP2; CTRP1 6.943 8.2167 4.6459 0.1468
KMM-1 CTRP2 6.961 13.6078 2.2356 8.5051
TF-1 CTRP2 7.2306 8.3713 4.6807 0.0509
REC-1 CTRP2 7.3787 9.898 4.1771 0.9374
L-428 CTRP2 7.4034 17.6472 0.5845 13.915
Toledo CTRP2 7.5134 9.5118 4.3843 0.3886
U266B1 CTRP2 9.2784 20.5368 0.4788 11.603
OCI-AML-5 CTRP2 9.5406 20.0117 0.8936 9.913
Kasumi-2 CTRP2 9.5641 22.638 -0.3308 13.7535
⏷ Show the Full List of 120 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 3.7824 4.8135 3.7226 8.6129
TE-9 CTRP2 2.6976 4.569 2.5956 15.9846
KYSE-180 CTRP2 2.9176 6.1082 2.3657 16.1797
TE-6 CTRP2 3.2364 4.8055 2.3246 3.1434
TE-10 CTRP2 3.4619 10.724 0.7978 20.7834
KYSE-450 CTRP2; CTRP1 3.5554 5.9641 3.1055 11.6567
KYSE-140 CTRP2; CTRP1 3.6066 6.2118 3.0585 11.6988
TE-4 CTRP2 4.1391 6.8253 3.3203 9.2068
TE-1 CTRP2 4.4418 7.0109 2.9095 4.6016
KYSE-150 CTRP2 4.7007 8.1973 3.1731 8.5543
KYSE-520 CTRP2 4.7475 10.1262 2.2521 12.283
KYSE-410 CTRP2; CTRP1 4.8333 7.038 3.8756 5.4218
TE-11 CTRP2 4.9079 7.2 3.8508 5.2869
KYSE-30 CTRP2 5.006 7.8304 3.6192 6.065
COLO 680N CTRP2 5.9033 7.6738 4.3579 1.5887
TE-5 CTRP2 5.9854 13.6112 1.5177 12.8721
TE-14 CTRP2 6.145 9.0969 3.8456 3.2686
KYSE-70 CTRP2 6.442 8.0808 3.5548 0.2212
OE33 CTRP2 6.9589 13.8178 2.1326 8.9089
OE19 CTRP2 7.0245 8.3422 4.6177 0.1445
KYSE-510 CTRP2 11.9358 22.6479 1.1055 6.711
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 6.0534 10.2283 3.2377 5.8514
KP-3 CTRP2; CTRP1 1.9887 7.8789 0.6686 25.1576
KP-4 CTRP2 2.544 5.9278 2.032 18.5014
HuP-T4 CTRP2; CTRP1 2.6064 5.596 2.2185 17.7046
Panc 03.27 CTRP2; CTRP1 2.7558 5.1311 2.5254 16.1362
SW1990 CTRP2 2.8094 20.6932 -4.7126 35.2876
BxPC-3 CTRP2 3.5119 7.3265 2.4652 14.2091
MIA PaCa-2 CTRP2 3.5195 5.7021 3.1636 11.4502
PSN1 CTRP2 3.8691 6.1413 3.3563 9.7476
PK-59 CTRP2 3.875 7.3613 2.2703 8.6054
PaTu 8902 CTRP2; CTRP1 3.8983 5.9675 3.4657 9.3281
HuP-T3 CTRP2 3.939 11.9493 0.6323 20.2656
SU.86.86 CTRP2 4.2572 7.6243 3.0514 10.0307
YAPC CTRP2 4.3801 7.6466 2.5455 6.342
SUIT-2 CTRP2; CTRP1 4.5955 6.6938 3.8292 6.1327
Capan-2 CTRP2; CTRP1 4.6692 11.7565 1.3801 15.988
Panc 10.05 CTRP2; CTRP1 4.8793 6.7309 4.0689 4.5168
HPAC CTRP2; CTRP1 4.9249 5.9004 4.5218 2.5278
KP-2 CTRP2 5.3247 10.576 2.5086 10.1036
TCC-Pan2 CTRP2 5.4258 9.4789 2.409 5.1791
QGP-1 CTRP2; CTRP1 5.4335 9.2533 3.2651 6.8389
SNU-410 CTRP2 5.561 9.2849 3.3378 6.235
HPAF-II CTRP2 5.5738 12.8763 1.5604 13.4487
Panc 08.13 CTRP2 5.6823 9.0009 3.5694 5.0718
Panc 02.03 CTRP2 5.9486 8.9707 3.7742 3.8257
Panc 05.04 CTRP2 5.9506 13.2258 0.9625 10.4312
Panc 04.03 CTRP2 6.0356 9.8635 3.4026 5.2054
SNU-213 CTRP2 6.184 15.6581 0.6548 15.6947
L3.3 CTRP2 6.1906 10.2311 3.333 5.2574
CFPAC-1 CTRP2; CTRP1 6.2245 10.6996 3.141 6.0597
PaTu 8988t CTRP2 6.4151 8.166 4.4237 0.8745
Hs 766T CTRP2 6.5297 8.3509 4.4035 0.851
Capan-1 CTRP2 6.7653 8.6298 4.4022 0.6988
PK-45H CTRP2 7.4464 13.8928 2.4262 7.0892
AsPC-1 CTRP2 7.5887 14.0624 2.4385 6.8551
PaTu 8988s CTRP2 8.328 14.4968 2.6932 5.0302
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 5.0262 13.6317 0.7355 17.5852
LOX-IMVI CTRP2 1.8113 5.4721 1.3906 23.0197
MDA-MB-435S CTRP2 1.8901 4.6808 1.5046 17.1103
Mel JuSo CTRP2 1.8973 3.0192 1.8951 20.9737
CJM [Human melanoma] CTRP2 2.1644 3.3028 2.1604 19.2003
Hs 944.T CTRP2; CTRP1 2.523 5.7656 2.0706 18.4967
G-361 CTRP2; CTRP1 2.6303 4.2164 2.5821 16.3271
RPMI-7951 CTRP2 2.8464 4.4465 2.7785 14.8747
IGR-1 CTRP2 3.0871 10.7727 0.4211 23.0216
MeWo CTRP2 3.1675 5.6992 2.7861 13.8791
WM266-4 CTRP2 3.3717 5.5519 3.0589 12.2673
COLO 741 CTRP2; CTRP1 3.8805 6.3294 3.2925 10.0551
SK-MEL-31 CTRP2 4.1863 9.9166 1.8608 15.0595
COLO 829 CTRP2 4.3831 8.1224 2.9247 10.2717
A101D CTRP2 4.4202 5.4922 4.2044 4.956
Hs 294T CTRP2 4.438 5.6279 4.1659 5.0588
WM115 CTRP2 4.5416 6.9335 3.6539 6.8933
IPC-298 CTRP2 4.6157 6.1106 3.475 1.8325
IGR-39 CTRP2 4.6594 10.6661 1.9066 13.8655
Hs 936.T CTRP2; CTRP1 4.8212 7.4594 3.6552 6.3695
Hs 852.T CTRP2; CTRP1 4.8778 6.7199 4.073 4.5029
UACC-62 CTRP2 4.8941 6.4387 4.2184 3.7733
SK-MEL-2 CTRP2 4.9656 5.805 4.5966 2.0401
WM1799 CTRP2 5.038 7.9539 2.8775 3.7565
Hs 895.T CTRP2 5.0619 8.3108 3.4258 6.7693
COLO 792 CTRP2 5.1348 10.2018 2.5406 10.3291
HT-144 CTRP2 5.2434 9.2554 3.1024 7.7839
WM793 CTRP2 5.3244 8.8825 2.6259 4.4061
SK-MEL-5 CTRP2; CTRP1 5.4133 6.9837 4.3735 2.2625
A2058 CTRP2 5.5237 7.6522 4.1152 3.0723
A-375 CTRP2; CTRP1 5.6085 8.3906 3.8259 4.2092
SK-MEL-30 CTRP2 5.742 7.0772 3.6466 0.2751
UACC-257 CTRP2 5.8428 10.5841 2.9085 7.5403
SK-MEL-28 CTRP2; CTRP1 6.1244 7.0196 4.7619 0.1914
Mel Ho CTRP2 6.2372 8.7612 4.0609 2.3195
SK-MEL-1 CTRP2; CTRP1 6.5013 11.1342 3.123 5.7269
SK-MEL-24 CTRP2 6.5362 11.9164 2.7582 7.0643
IGR-37 CTRP2 6.7535 8.0445 4.6213 0.2079
WT2-iPS CTRP2 6.7606 7.9261 4.6664 0.1364
Hs 940.T CTRP2 6.9327 12.035 2.9697 5.6677
Hs 934.T CTRP2 7.1656 8.4501 4.6315 0.1021
COLO 800 CTRP2 7.5949 14.2633 2.3478 7.1916
Hs 839.T CTRP2 7.9659 16.6026 1.4813 9.9158
Hs 688(A).T CTRP2 8.9868 24.5979 -1.6734 18.2988
SK-MEL-3 CTRP2 9.0306 17.547 1.7203 7.7022
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 CTRP2 7.2594 17.3652 0.6183 14.0247
Cancer Drug Sensitivity Data Curated from 14 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CHP-212 CTRP2 1.8787 3.4954 1.859 21.1565
KP-N-SI9s CTRP2 2.246 4.2823 2.1596 18.9377
SK-N-SH CTRP2 3.5369 6.4919 2.8618 12.5707
IMR-32 CTRP2 3.8958 14.9028 -0.872 25.1439
NB1 CTRP2 4.2789 7.294 3.2317 9.2377
MHH-NB-11 CTRP2 4.5777 6.447 3.9243 5.6937
SK-N-AS CTRP2 5.495 7.0618 4.3821 2.025
SK-N-FI CTRP2 5.5444 11.3253 2.3103 10.5147
SK-N-DZ CTRP2 5.7353 7.8233 4.18 2.4962
SK-N-BE(2) CTRP2 5.8135 12.1304 2.1202 10.8059
CHP-126 CTRP2 6.3604 12.8035 2.1995 9.5707
KP-N-YN CTRP2 6.6704 11.8693 2.8735 6.409
NH-6 CTRP2 6.7544 11.3451 3.1798 5.0815
Kelly CTRP2 7.1092 16.8022 0.7849 13.6848
⏷ Show the Full List of 14 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1079 CTRP2 -0.7103 1.4291 -0.7156 38.356
HuH-28 CTRP2 0.8643 5.5376 0.3389 29.6196
SNU-308 CTRP2 3.9912 6.3628 3.3849 9.3163
SNU-478 CTRP2 4.3035 7.536 3.1378 9.5683
HuCC-T1 CTRP2 5.1025 7.0188 4.1052 3.837
SNU-869 CTRP2 5.8767 12.0814 2.1931 10.4028
SNU-1196 CTRP2 5.9168 8.8151 3.8273 3.657
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MG-63 CTRP2 1.9031 4.1063 1.8192 21.2129
U2OS CTRP2; CTRP1 2.5196 5.7297 2.0793 18.4741
CAL-78 CTRP2 2.7338 5.1692 2.4876 16.2588
MHH-ES-1 CTRP2 3.0036 4.4356 2.949 13.7819
A-673 CTRP2 3.3385 5.2435 3.1248 12.1206
SJSA-1 CTRP2 4.2863 7.4702 3.1535 9.5428
SaOS-2 CTRP2 4.7647 7.5783 3.5374 6.8959
HOS CTRP2 4.9189 6.6458 4.1368 4.0643
SW1353 CTRP2 5.2792 9.3168 3.1005 7.7257
Hs 822.T CTRP2 5.5611 7.4803 4.2255 2.5635
Hs 888.T CTRP2 5.6947 9.1466 3.5068 5.3106
SK-ES-1 CTRP2 6.0247 8.886 3.8664 3.3484
G-292 clone A141B1 CTRP2 6.9027 14.4006 1.81 10.2391
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 69 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MDA-MB-231 CTRP2 1.7957 6.036 1.1861 23.8045
MDA-MB-157 CTRP2 2.697 5.979 2.178 17.515
Hs 578Bst CTRP2 2.9768 11.0709 0.1725 24.132
HCC1954 CTRP2 2.9843 5.8461 2.5356 15.3468
HCC1806 CTRP2 2.9945 4.5816 2.9145 13.9308
CAL-51 CTRP2 3.3751 6.3794 2.7411 13.475
JIMT-1 CTRP2 3.5591 4.9288 3.4536 10.2616
HMC-1-8 CTRP2 3.623 5.8005 3.2368 10.8804
CAL-120 CTRP2 4.044 6.4898 3.381 9.1976
BT-20 CTRP2 4.6395 7.2556 3.5856 6.9607
CAL-148 CTRP2 4.6851 8.1542 3.1808 8.5546
HDQ-P1 CTRP2 4.8784 9.5853 2.6342 10.442
HCC1419 CTRP2 5.1072 13.1353 1.0511 16.2742
HCC1569 CTRP2 5.3528 7.5484 4.0392 3.6663
CAL-85-1 CTRP2 5.5429 11.4601 2.2419 10.7956
HCC1143 CTRP2 5.6556 10.5857 2.034 6.4284
HCC1395 CTRP2 5.8831 16.2745 0.1121 18.0839
ZR-75-1 CTRP2 6.1441 11.1936 2.0672 5.5884
ZR-75-30 CTRP2 6.1497 15.7411 0.5869 15.9926
CAMA-1 CTRP2 6.2773 8.8759 4.0326 2.3795
MCF-7 CTRP2; CTRP1 6.2794 9.1891 3.9007 2.9523
HCC1937 CTRP2 6.4558 11.8987 2.7104 7.3766
HCC1428 CTRP2 6.4775 11.5611 2.8893 6.6255
HCC2218 CTRP2 6.6019 15.1842 1.2067 12.9911
SK-BR-3 CTRP2 6.8012 9.0555 4.2447 1.1338
MDA-MB-453 CTRP2 6.858 13.9248 2.0098 9.5372
KPL-1 CTRP2 6.9168 12.7505 2.618 7.0704
HCC1500 CTRP2 7.0094 39.7297 -10.6891 34.9052
BT-549 CTRP2 7.1041 17.8801 0.2517 15.511
MDA-MB-361 CTRP2 7.1541 8.799 4.5035 0.2893
BT-474 CTRP2 7.2383 8.644 4.5906 0.136
AU565 CTRP2 7.2803 11.1771 3.58 2.9478
T-47D CTRP2 7.4713 11.5771 3.5102 3.0024
HCC38 CTRP2 7.4727 15.0667 1.884 9.1161
HCC202 CTRP2 7.5425 17.3354 0.8358 12.8327
BT 416 CTRP2 0.4029 7.2264 -0.7482 34.3887
BT 422 CTRP2 5.4914 8.6218 3.6132 5.206
BT 172 CTRP2 5.7027 7.8556 4.1424 2.6933
BT 131 CTRP2 5.7122 8.8376 3.6715 4.6025
BT 498 CTRP2 5.7457 10.1254 3.0621 7.0679
BT 444 CTRP2 5.9044 8.7562 3.8471 3.5947
BT 286 CTRP2 5.9463 10.7102 2.9235 7.3087
BT 440 CTRP2 5.9569 7.725 4.3666 1.4956
BT 245 CTRP2 6.0618 8.9315 3.8693 3.2862
BT 248 CTRP2 6.0625 13.7973 1.4848 12.8633
BT 504 CTRP2 6.0738 10.1545 3.2881 5.6142
BT 320 CTRP2 6.1033 7.2347 4.6555 0.413
BT 482 CTRP2 6.1491 7.9725 4.3662 1.2959
BT 428 CTRP2 6.2725 7.9235 4.4536 0.892
BT 231 CTRP2 6.3297 14.0709 1.5524 12.1475
BT 139 CTRP2 6.411 8.8801 4.1102 1.9432
BT 359 CTRP2 6.4304 9.3641 3.9013 2.6965
BT 239 CTRP2 6.4795 14.4917 1.4569 12.26
BT164 CTRP2 6.4954 13.4568 1.9776 10.2292
BT 271 CTRP2 6.5662 7.9135 4.5942 0.328
BT 145 CTRP2 6.5999 13.7027 1.9333 10.2357
BT 328 CTRP2 6.7114 8.4532 4.4479 0.6085
BT 340 CTRP2 6.8967 12.0194 2.9535 5.7793
BT 216 CTRP2 6.9962 8.8618 4.4143 0.5412
BT147 CTRP2 7.5848 9.6374 4.3666 0.3972
BT 112 CTRP2 7.5931 15.4254 1.7936 9.2857
BT 330 CTRP2 7.8147 18.3937 0.5139 13.526
BT 187 CTRP2 9.2941 17.926 1.7062 7.447
BT 232 CTRP2 10.0626 22.1813 0.2099 11.4709
BT 179 CTRP2 10.0957 20.865 0.8425 9.4229
BT 224 CTRP2 10.1628 18.7795 1.8276 6.1141
BT 159 CTRP2 12.6731 25.6841 0.1751 8.7541
BT 333 CTRP2 13.1143 27.2073 -0.2536 9.5339
BT 228 CTRP2 13.4504 29.241 -0.974 11.1389
⏷ Show the Full List of 69 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 2.7466 4.4924 2.663 15.5943
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AM-38 CTRP2 -10.6341 12.7435 -14.6474 67.681
SNU-1105 CTRP2 0.6759 3.2904 0.6168 29.3019
GB-1 CTRP2 0.6801 4.1047 0.5012 29.6773
SNU-466 CTRP2 0.8736 4.7089 0.5798 28.7829
SF295 CTRP2; CTRP1 1.2444 3.8901 1.1471 25.7179
SNU-201 CTRP2 1.7473 6.2095 1.0721 24.359
SNU-626 CTRP2 1.8008 5.1117 1.4859 22.7088
Daoy CTRP2 1.9674 4.0188 1.9006 20.7259
ONS-76 CTRP2 2.1356 3.8683 2.0971 19.5088
SF126 CTRP2 2.2698 3.7745 2.2463 18.5638
LN-18 CTRP2 2.4332 4.3851 2.3438 17.7016
LN-229 CTRP2; CTRP1 2.7965 4.9743 2.6125 15.6983
YKG-1 CTRP2 2.8294 5.4309 2.5115 15.8861
SF268 CTRP2 2.9887 5.8608 2.535 15.3367
KNS-60 CTRP2 3.0575 3.7751 2.6957 1.7224
CAS-1 CTRP2 3.0934 7.2282 2.0847 16.7909
SNU-489 CTRP2 3.1363 5.1549 2.9308 13.4349
KG-1-C CTRP2 3.2336 8.6447 1.578 18.4117
KALS-1 CTRP2 3.5439 5.7983 3.1532 11.4211
A-172 CTRP2 3.6359 8.2343 2.1641 15.1099
Hs 683 CTRP2 3.7356 7.5997 2.5609 13.269
U-118MG CTRP2 3.8964 7.0605 2.9712 11.2162
U-251MG CTRP2 4.0014 7.3091 2.9577 11.0151
SNU-738 CTRP2 4.0236 5.7941 3.6635 8.1328
KNS-81 CTRP2 4.19 7.6638 2.9688 10.5257
YH-13 CTRP2 4.3766 11.3377 1.3253 16.7444
NMC-G1 CTRP2 4.5087 7.706 3.2444 8.6671
42-MG-BA CTRP2 4.5517 8.1923 3.0431 9.4124
U-87MG ATCC CTRP2 4.9745 10.0903 2.4629 10.9612
T98G CTRP2 5.0426 11.2054 1.9624 12.87
D283 Med CTRP2 5.0679 7.869 3.6516 5.8089
KNS-42 CTRP2 5.1913 6.9289 4.2216 3.1851
GaMG CTRP2; CTRP1 5.2143 7.3427 4.0437 3.9726
CCF-STTG1 CTRP2 5.3071 7.8732 3.8425 4.5671
GOS-3 CTRP2 5.3133 7.3219 4.1212 3.3914
SF539 CTRP2 5.34 9.1798 3.2176 7.125
SW1088 CTRP2 5.852 10.0273 3.1898 6.3653
DBTRG-05MG CTRP2 5.8743 9.4836 3.4726 5.1662
SW1783 CTRP2 6.0126 11.9687 2.3523 9.5293
GMS-10 CTRP2 6.1374 15.8179 0.5392 16.1802
TM-31 CTRP2 6.4158 9.6421 3.7632 3.2423
SNB-75 CTRP2 6.8143 12.0048 2.9057 6.0796
M059K CTRP2 7.6233 17.0501 1.0313 12.0234
8-MG-BA CTRP2 7.8915 14.5513 2.4024 6.6067
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RL95-2 CTRP2 0.7868 3.731 0.6794 28.7266
HEC-1-B CTRP2 2.5236 6.3502 1.8522 19.2358
KLE CTRP2; CTRP1 3.3068 7.1902 2.3257 15.3675
HEC-251 CTRP2; CTRP1 3.4456 6.0637 2.9494 12.5593
HEC-265 CTRP2; CTRP1 3.4667 4.6789 3.4083 10.7966
HEC-50B CTRP2 3.5438 8.1656 2.1069 15.5629
ESS-1 CTRP2 3.7137 5.8253 3.3235 10.2963
MFE-319 CTRP2; CTRP1 3.8181 5.3054 3.6302 8.927
HEC-6 CTRP2; CTRP1 4.0627 5.6358 3.7736 7.6889
JHUEM-3 CTRP2 4.197 9.6976 1.9787 14.5627
HEC-1-A CTRP2 4.2473 6.2542 3.6925 7.4351
JHUEM-2 CTRP2; CTRP1 4.264 6.8851 3.421 8.5813
HEC-108 CTRP2; CTRP1 4.851 6.3049 4.2551 3.7986
EN CTRP2 5.0584 8.2071 3.4747 6.5709
HEC-151 CTRP2; CTRP1 5.0993 7.5456 3.8491 5.003
HEC-59 CTRP2; CTRP1 5.9389 7.808 4.3301 1.7218
EFE-184 CTRP2 5.9607 8.9477 3.7935 3.7302
MFE-296 CTRP2 6.1268 10.4941 3.1605 6.0539
JHUEM-1 CTRP2 6.8628 11.1533 3.3397 4.3194
Ishikawa (Heraklio) 02 ER- CTRP2; CTRP1 4.9433 6.1127 4.4328 2.8608
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TUHR10TKB CTRP2 1.6633 4.4334 1.5016 23.0802
TUHR14TKB CTRP2 2.7378 12.6988 -0.8417 43.7891
VMRC-RCW CTRP2; CTRP1 2.9323 5.8258 2.4912 15.7436
UO-31 CTRP2 3.1894 6.4858 2.5024 14.9049
ACHN CTRP2 3.3401 8.615 1.6961 17.6879
BFTC-909 CTRP2 3.9014 5.7408 3.5561 8.8827
769-P CTRP2 3.9067 6.4469 3.2614 10.0251
A-498 CTRP2 3.9142 4.9487 3.8357 7.802
TUHR4TKB CTRP2 3.9347 8.1092 2.5113 12.9941
OS-RC-2 CTRP2 4.747 9.7635 2.4326 11.5418
KMRC-1 CTRP2 4.7859 7.7962 3.4475 7.2283
KMRC-20 CTRP2 5.1022 11.1124 2.0584 12.3663
CAL-54 CTRP2 5.5458 8.5175 3.706 4.7289
SNU-1272 CTRP2 5.7028 10.1021 3.0411 7.2271
786-O CTRP2 5.7056 10.2881 2.9511 7.5946
KMRC-3 CTRP2 6.3629 9.8794 3.6177 3.878
KMRC-2 CTRP2 6.4819 11.7854 2.7838 7.0426
RCC10RGB CTRP2; CTRP1 6.507 8.0849 4.5149 0.5972
VMRC-RCZ CTRP2 6.8757 9.9298 3.9063 2.1972
Caki-1 CTRP2 7.9281 13.892 2.7303 5.3432
Caki-2 CTRP2 8.5447 19.0612 0.6948 11.8683
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 50 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW403 CTRP1 2.6075 4.9978 2.4001 36.3339
SNU-C2A CTRP2; CTRP1 2.7922 7.6786 1.5839 19.5996
HCT 15 CTRP2 2.8384 5.9921 2.3249 16.5581
SK-CO-1 CTRP2; CTRP1 2.8597 5.0928 2.6495 15.3726
HT115 CTRP2; CTRP1 3.3627 4.634 3.304 11.4896
SW48 CTRP2; CTRP1 3.7814 5.0506 3.667 8.9018
DLD-1 CTRP2; CTRP1 3.8504 5.2397 3.6866 8.6238
LS513 CTRP2; CTRP1 3.9269 7.8664 2.6279 12.6185
GP2d CTRP2; CTRP1 3.9517 5.583 3.6757 8.3723
COLO205 CTRP2; CTRP1 4.2372 5.5235 4.0032 6.325
CL-11 CTRP2 4.4326 8.8839 2.5936 11.5355
SNU-81 CTRP2; CTRP1 4.6462 7.3919 3.5328 7.2513
LS411N CTRP2; CTRP1 4.6826 6.509 4.0005 5.2275
LS180 CTRP2; CTRP1 4.8113 6.6161 4.0654 4.6754
T84 CTRP2 4.8253 7.0857 3.8359 5.5191
NCI-H716 CTRP2 4.8379 8.0952 3.3437 7.5571
CW-2 CTRP2; CTRP1 4.9461 7.8378 3.5743 6.4549
SW480 CTRP1 5.051 10.3587 2.4024 22.1178
NCI-H747 CTRP2 5.0559 8.0103 3.571 6.1707
OUMS-23 CTRP2 5.0565 6.0991 4.5271 2.1513
COLO 320 CTRP2; CTRP1 5.1335 8.6777 3.3113 7.1953
SNU-1040 CTRP1 5.3224 6.6927 4.4498 4.4904
HCT 116 CTRP2; CTRP1 5.4616 7.4796 4.1656 3.0426
CCK-81 CTRP2 5.5455 8.9485 3.4926 5.617
LS1034 CTRP2 5.619 7.4267 4.2914 2.2127
SNU-C5 CTRP2; CTRP1 5.6562 11.1481 2.4966 9.6298
MDST8 CTRP2; CTRP1 5.7362 11.0676 2.5986 9.072
SW1116 CTRP2 5.7521 9.3585 3.4449 5.4736
COLO201 CTRP2 5.7605 8.2826 3.9763 3.2813
CL-34 CTRP1 5.7673 7.8567 4.1972 5.2733
LS123 CTRP2; CTRP1 6.1893 14.6329 1.1783 13.863
C2BBe1 CTRP2; CTRP1 6.2103 10.4791 3.2381 5.6876
HCT 8 CTRP2; CTRP1 6.2103 9.619 3.6523 4.0202
RCM-1 [Human ESC] CTRP2; CTRP1 6.2206 8.5709 4.1506 2.0706
RKO CTRP2; CTRP1 6.2883 9.9681 3.5378 4.3689
COLO 678 CTRP2; CTRP1 6.5037 16.0438 0.7191 14.9772
HT-55 CTRP2; CTRP1 6.5078 7.8425 4.6105 0.3561
SNU-1033 CTRP2 6.5482 16.6451 0.4447 15.7886
SNU-61 CTRP2; CTRP1 6.5548 21.0424 -1.723 22.2787
HT-29 CTRP2; CTRP1 6.5823 7.736 4.6807 0.187
SNU-175 CTRP1 6.65 12.2556 2.6848 14.4062
SW620 CTRP2; CTRP1 6.6626 11.7948 2.9156 6.3248
KM12 CTRP2; CTRP1 6.6955 8.61 4.3908 0.8248
SW1417 CTRP2 6.6963 16.6901 0.5344 15.2306
SW948 CTRP1 6.7739 8.2113 4.5821 0.6559
SNU-C4 CTRP2; CTRP1 7.0218 8.4283 4.6004 0.194
CL-40 CTRP1 7.047 8.7927 4.4763 0.8931
LoVo CTRP2; CTRP1 7.0681 12.5076 2.8464 6.0389
NCI-H508 CTRP2; CTRP1 7.2424 8.45 4.6728 0.0682
SNU-407 CTRP2 7.3372 11.8702 3.3001 3.9073
⏷ Show the Full List of 50 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-886 CTRP2 -1.7797 3.0338 -1.966 45.753
SNU-878 CTRP2 1.074 2.9464 1.058 26.5046
SNU-182 CTRP2 1.4445 7.778 0.1376 28.4623
SNU-423 CTRP2 1.9732 4.8089 1.754 21.2209
JHH-2 CTRP2 2.3491 6.0361 1.7829 19.9934
Li-7 CTRP2 2.4002 6.3063 1.7373 20.0176
SNU-449 CTRP2; CTRP1 2.6929 5.3994 2.3764 16.868
SNU-387 CTRP2 2.8402 8.083 1.4456 19.9253
SNU-761 CTRP2 2.842 3.4875 2.6421 2.5174
SNU-398 CTRP2; CTRP1 3.8849 8.4997 2.2835 14.1158
SK-HEP-1 CTRP2 4.3702 7.0783 3.4225 8.2407
HLF CTRP2 4.6438 7.2183 3.6079 6.8585
JHH-4 CTRP2 4.7232 7.7211 3.4298 7.4329
JHH-5 CTRP2 4.7511 11.5873 1.5254 15.1856
PLC/PRF/5 CTRP2 4.8426 7.9415 3.4244 7.2091
JHH-6 CTRP2; CTRP1 5.1137 6.8699 4.1986 3.5082
Hep 3B2.1-7 CTRP2 5.6294 9.0495 3.506 5.421
HuH-6 CTRP2 6.0336 9.055 3.7915 3.635
JHH-1 CTRP2 6.3402 7.8658 4.5114 0.6655
Hep-G2 CTRP2; CTRP1 6.5383 8.3144 4.4362 0.8002
SNU-475 CTRP2 7.1958 12.0702 3.1216 4.7449
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 156 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC44 CTRP2; CTRP1 -0.4086 2.4893 -0.4497 36.5216
LC-1F CTRP2 -0.044 11.4204 -7.8758 23.3474
HCC2279 CTRP2 0.547 4.2809 0.3216 30.7148
NCI-H1734 CTRP2 0.815 3.5181 0.7384 28.4349
HOP-92 CTRP2 0.8442 3.3303 0.7903 28.1635
PC-14 CTRP2 0.8471 3.0523 0.8169 28.0645
Lu-99 CTRP2; CTRP1 1.0325 3.4822 0.9738 26.9962
HCC15 CTRP2; CTRP1 1.203 3.0739 1.1849 25.7242
NCI-H661 CTRP2; CTRP1 1.2435 3.7552 1.1651 25.6592
NCI-H1755 CTRP2; CTRP1 1.3883 4.2188 1.2472 24.9115
NCI-H1915 CTRP2; CTRP1 1.6309 3.5491 1.5971 22.9291
NCI-H82 CTRP1 1.8643 6.1803 1.2128 46.895
SW1573 CTRP2 1.9895 11.7164 -1.0858 30.4236
NCI-H292 CTRP2 2.0317 4.3003 1.9257 20.4333
NCI-H446 CTRP2 2.109 4.2333 2.0204 19.858
NCI-H2286 CTRP2; CTRP1 2.1158 4.0944 2.0497 19.8121
HCC1195 CTRP2; CTRP1 2.3381 4.8281 2.1493 18.7634
EBC-1 CTRP2; CTRP1 2.39 4.8403 2.2029 18.4121
NCI-H838 CTRP2 2.4184 4.5819 2.2903 17.9356
HCC78 CTRP2; CTRP1 2.4292 3.8821 2.4049 17.584
COR-L279 CTRP1 2.5475 4.0985 2.5084 36.1404
NCI-H1838 CTRP2 2.5504 6.2432 1.9218 18.8973
NCI-H2085 CTRP2 2.5882 5.9699 2.0644 18.2529
NCI-H1299 CTRP2; CTRP1 2.6091 4.9317 2.419 16.9661
LXF 289 CTRP2; CTRP1 2.7021 4.0673 2.6747 15.7781
NCI-H1666 CTRP2; CTRP1 2.7453 5.9138 2.2579 17.1555
Lu-65 CTRP1 2.8183 4.9003 2.6551 33.1329
NCI-H1048 CTRP1 2.9011 4.7118 2.7889 31.6186
NCI-H2087 CTRP2 2.9195 6.3515 2.2726 16.53
HCC366 CTRP2 2.9745 7.8993 1.6642 18.7375
NCI-H810 CTRP1 3.0079 5.6812 2.6243 31.9578
LCLC-103H CTRP2; CTRP1 3.0537 4.3499 3.0155 13.475
NCI-H1155 CTRP2 3.0553 4.5864 2.9793 13.5115
DMS 273 CTRP2; CTRP1 3.0857 4.638 3.0041 13.4126
LOU-NH91 CTRP2 3.0864 5.9108 2.6213 14.7328
NCI-H23 CTRP1 3.2838 5.4283 3.0095 27.3877
SW1271 CTRP2 3.3244 4.9654 3.1883 11.9325
NCI-H1975 CTRP2; CTRP1 3.3657 5.4119 3.1039 12.2016
NCI-H522 CTRP1 3.3714 6.7019 2.606 29.6143
RERF-LC-A1 CTRP2 3.4013 5.4039 3.1416 11.8729
NCI-H196 CTRP2 3.4572 6.1656 2.9156 12.5748
NCI-H211 CTRP2 3.4862 8.1501 2.0579 15.8993
NCI-H1355 CTRP2; CTRP1 3.565 5.3428 3.343 10.7322
SBC-5 CTRP2 3.5882 6.3432 2.9786 11.9762
T3M-10 CTRP2; CTRP1 3.6419 7.5751 2.487 13.878
NCI-H1793 CTRP2; CTRP1 3.7282 6.9191 2.8746 12.108
NCI-H2009 CTRP2; CTRP1 3.7286 6.3446 3.1293 11.0965
NCI-H1650 CTRP2 3.7486 7.2713 2.7269 12.5675
HARA [Human squamous cell lung carcinoma] CTRP2; CTRP1 3.8602 6.8846 3.0229 11.1815
Calu-3 CTRP2; CTRP1 3.8654 6.7289 3.0991 10.8628
NCI-H2291 CTRP2 3.8657 8.7419 2.1404 14.6605
NCI-H647 CTRP2 3.923 9.0289 2.0547 14.8736
NCI-H358 CTRP2; CTRP1 3.9303 6.1268 3.4317 9.3756
COR-L105 CTRP2 3.9919 7.1271 3.0342 10.7271
SCLC-21H CTRP1 4.0248 6.668 3.2869 20.719
NCI-H1581 CTRP2 4.0505 5.7755 3.6994 7.9206
NCI-H1373 CTRP2; CTRP1 4.0621 5.4321 3.8504 7.3985
NCI-H1930 CTRP1 4.1027 7.088 3.1681 21.234
NCI-H1563 CTRP2 4.1315 8.1293 2.6879 11.8152
NCI-H2405 CTRP2; CTRP1 4.1348 7.2586 3.1184 10.1244
NCI-H2228 CTRP2 4.1519 6.0451 3.6897 7.6897
RERF-LC-KJ CTRP1 4.1571 8.6865 2.4479 26.0611
NCI-H727 CTRP2; CTRP1 4.1944 8.787 2.4331 12.7991
HOP-62 CTRP2 4.2198 6.8217 3.4009 8.6841
EPLC-272H CTRP2; CTRP1 4.2392 7.553 3.0768 10.0506
NCI-H1573 CTRP2; CTRP1 4.2649 7.4309 3.1601 9.6485
NCI-H1435 CTRP2; CTRP1 4.2659 6.2306 3.7285 7.3311
Calu-1 CTRP2 4.2728 9.8545 1.9695 14.4333
SK-MES-1 CTRP2 4.2925 6.4495 3.6471 7.506
NCI-H1781 CTRP1 4.4253 10.367 1.8599 28.0625
HCC33 CTRP1 4.4871 5.897 4.1027 11.3186
LCLC-97TM1 CTRP2; CTRP1 4.507 8.0755 3.0691 9.4831
A-549 CTRP2; CTRP1 4.5174 6.4357 3.8799 6.1044
HCC1438 CTRP2 4.5192 5.8125 4.1669 4.8453
Calu-6 CTRP2; CTRP1 4.6112 5.9651 4.1943 4.5972
LC-1/sq-SF CTRP2; CTRP1 4.6956 7.9637 3.2936 8.1441
NCI-H1703 CTRP2 4.7132 9.0705 2.7491 10.2989
NCI-H1568 CTRP2; CTRP1 4.7214 7.7632 3.4161 7.5778
NCI-H2122 CTRP2; CTRP1 4.7622 6.6317 4.0133 4.9981
HCC2108 CTRP2; CTRP1 4.7855 7.9113 3.3989 7.5161
NCI-H2171 CTRP2 4.8066 7.9366 3.3956 7.4033
KNS-62 CTRP2; CTRP1 4.812 7.9375 3.409 7.4194
NCI-H226 CTRP2 4.8238 7.0183 3.8681 5.3875
NCI-H2029 CTRP2; CTRP1 4.8326 10.2847 2.2551 12.1755
NCI-H1792 CTRP2; CTRP1 4.8555 7.665 3.5827 6.6025
COLO 668 CTRP2; CTRP1 4.8598 7.0056 3.915 5.2019
NCI-H1693 CTRP2 4.8693 7.1557 3.8395 5.4129
BEN CTRP2; CTRP1 4.8798 5.6816 4.5881 2.3516
SHP-77 CTRP2; CTRP1 4.9431 9.035 2.9735 8.9788
CAL-12T CTRP2; CTRP1 4.9585 7.926 3.5409 6.5707
COR-L88 CTRP1 4.9639 6.1557 4.4294 6.0788
NCI-H650 CTRP2; CTRP1 5.0383 6.9973 4.0724 4.1823
NCI-H1339 CTRP2 5.0477 8.5113 3.3137 7.2675
IA-LM CTRP2 5.1503 8.1723 3.5678 6.0054
RERF-LC-Ad1 CTRP2 5.2584 15.117 0.1853 19.0271
DMS 79 CTRP2 5.2914 10.2265 2.6563 9.5547
NCI-H596 CTRP1 5.3263 6.6564 4.4706 4.2933
NCI-H2126 CTRP2; CTRP1 5.3351 8.6071 3.5093 5.9934
NCI-H889 CTRP2 5.3448 7.5161 4.0491 3.6387
MOR/CPR CTRP2 5.3621 6.8624 4.3846 2.2169
NCI-H1437 CTRP1 5.3634 7.5363 4.0639 7.7747
NCI-H1944 CTRP1 5.3796 8.8331 3.4319 13.1765
NCI-H322 CTRP2 5.4236 8.2408 3.7502 4.7507
NCI-H2030 CTRP2; CTRP1 5.4562 8.3923 3.7106 4.9404
SK-LU-1 CTRP2; CTRP1 5.4897 8.8235 3.5225 5.667
HCC1359 CTRP1 5.6256 8.6804 3.696 10.0424
HCC1588 CTRP2 5.6327 8.4696 3.7939 4.2239
NCI-H1963 CTRP1 5.6594 7.4669 4.3111 4.6211
NCI-H520 CTRP2 5.6622 8.4472 3.8264 4.0435
NCI-H3255 CTRP1 5.6745 7.2839 4.408 3.7537
NCI-H2342 CTRP2; CTRP1 5.6802 7.5957 4.2635 2.3151
VMRC-LCD CTRP2; CTRP1 5.705 9.5508 3.326 6.1206
HCC95 CTRP2 5.7364 7.8406 4.1725 2.5249
NCI-H2081 CTRP1 5.8201 7.5587 4.3721 3.6575
NCI-H2106 CTRP2 5.882 14.1339 1.1774 14.3428
NCI-H69 CTRP2 5.8862 8.5789 3.92 3.3272
HCC827 CTRP2; CTRP1 5.9197 9.0901 3.7078 4.2131
NCI-H2110 CTRP1 5.9313 8.2443 4.1213 5.44
DMS 53 CTRP2 6.0418 8.8112 3.9133 3.1387
NCI-H1341 CTRP2 6.0761 11.241 2.7582 7.7753
HCC4006 CTRP2; CTRP1 6.1652 8.2037 4.2847 1.6365
NCI-H1836 CTRP1 6.2082 7.8227 4.4764 1.9946
NCI-H2444 CTRP2 6.2471 7.3208 4.6853 0.2666
Sq-1 CTRP2; CTRP1 6.2515 9.4361 3.7666 3.5118
EKVX CTRP2 6.2857 10.1724 3.4266 4.7434
COR-L51 CTRP1 6.3121 8.2491 4.3474 2.7213
NCI-H1105 CTRP2; CTRP1 6.3902 8.3501 4.3455 1.204
NCI-H2073 CTRP1 6.4115 9.1236 4.0125 5.0647
NCI-H1694 CTRP2; CTRP1 6.4546 9.0412 4.0755 2.0892
NCI-H841 CTRP1 6.568 11.3292 3.0748 11.9133
ChaGo-K-1 CTRP2; CTRP1 6.5816 9.9553 3.7334 3.2238
NCI-H2023 CTRP2; CTRP1 6.6097 9.5731 3.9258 2.4695
NCI-H2196 CTRP2 6.6376 8.3628 4.4502 0.646
NCI-H1395 CTRP2 6.7384 16.8873 0.4687 15.385
NCI-H1876 CTRP1 6.7603 9.8195 3.9025 5.0979
NCI-H2170 CTRP2 6.8061 9.7379 3.9522 2.1042
NCI-H460 CTRP2; CTRP1 6.8305 8.0568 4.6605 0.1522
COR-L95 CTRP2 6.8666 8.1409 4.63 0.1634
NCI-H1092 CTRP2 6.8796 13.7775 2.0966 9.1675
NCI-H526 CTRP2 6.8975 14.0138 1.9945 9.5367
NCI-H2141 CTRP1 6.9408 9.3129 4.22 2.4826
HCC2935 CTRP2; CTRP1 7.0382 10.6285 3.6994 2.8347
COR-L23 CTRP1 7.0978 8.6532 4.5486 0.5522
RERF-LC-Ad2 CTRP2 7.155 14.3426 2.015 9.0746
NCI-H1385 CTRP2 7.1552 34.1244 -7.7762 31.844
HCC1833 CTRP2; CTRP1 7.1964 16.5147 1 12.8496
DV-90 CTRP1 7.3723 8.9754 4.538 0.4285
DMS 454 CTRP2 7.5269 9.5221 4.3859 0.3808
NCI-H1623 CTRP2 7.5788 9.6478 4.3603 0.4114
COLO 699 CTRP2; CTRP1 7.7252 16.1016 1.5705 9.9914
DMS 114 CTRP2 7.84 19.1303 0.1735 14.6133
HCC1171 CTRP2 7.9006 20.4685 -0.4363 16.4341
NCI-H1869 CTRP2 8.0766 16.2318 1.731 8.8561
NCI-H441 CTRP2; CTRP1 8.3355 16.5351 1.7676 8.4492
NCI-H2172 CTRP2; CTRP1 8.9745 16.0897 2.3639 5.567
Hs 888.Lu CTRP2 4.3941 9.3665 2.3201 12.7453
⏷ Show the Full List of 156 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 43 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 5.1305 13.1688 1.0537 16.2185
OVSAHO CTRP2 1.1794 4.2049 1.0224 26.2845
A2780 CTRP2; CTRP1 1.9832 4.9625 1.7281 21.3583
HEY A8 CTRP2; CTRP1 2.2711 4.7351 2.0984 19.1512
Kuramochi CTRP2 2.4297 8.5557 0.8174 23.3396
MCAS CTRP2 2.4375 6.579 1.6712 20.1603
OVCAR-8 CTRP2; CTRP1 2.4757 5.1735 2.2077 18.133
SNU-119 CTRP2 2.7084 4.9351 2.5241 16.2045
SNU-8 CTRP2 2.8648 4.7195 2.7459 14.9308
OVKATE CTRP1 2.9804 6.0472 2.4607 33.1697
OVK18 CTRP2; CTRP1 3.2559 6.8251 2.4335 15.0767
OVISE CTRP2 3.324 4.6223 3.263 11.6697
JHOS-4 CTRP1 3.5125 5.0699 3.3682 23.1683
OVCAR-5 CTRP2 3.6446 6.6406 2.9079 12.1068
COV434 CTRP2; CTRP1 3.945 7.9291 2.6152 12.6271
SK-OV-3 CTRP2; CTRP1 4.0293 5.6849 3.7187 7.992
IGROV-1 CTRP2; CTRP1 4.2189 6.6427 3.4913 8.404
OVMANA CTRP1 4.3722 7.2877 3.3308 18.509
OV-90 CTRP2; CTRP1 4.4121 7.344 3.3409 8.5666
Caov-3 CTRP2; CTRP1 4.5708 8.9398 2.698 10.8883
OVTOKO CTRP2 4.5933 14.6205 -0.1246 21.3872
OV56 CTRP2 4.9535 6.4663 4.2563 3.4923
TYK-nu CTRP2; CTRP1 4.9992 7.6617 3.7074 5.7912
DOV13 CTRP2 5.0636 7.7463 3.7094 5.5742
FU-OV-1 CTRP2 5.1383 8.9793 3.1546 7.7619
COV318 CTRP1 5.2494 7.1922 4.1465 7.4636
EFO-21 CTRP2; CTRP1 5.3483 7.9493 3.8472 4.5568
SNU-840 CTRP2; CTRP1 5.3578 12.2144 1.7271 13.2731
ONCO-DG-1 CTRP2 5.4914 8.1245 3.8591 4.183
JHOM-1 CTRP1 5.5755 7.467 4.2535 5.3775
ES2 CTRP2 5.7277 9.705 3.2561 6.2943
RMG-I CTRP2; CTRP1 6.0281 14.7287 1.006 14.7795
EFO-27 CTRP2; CTRP1 6.1517 8.9494 3.9315 2.9951
COV362 CTRP2; CTRP1 6.1726 11.5666 2.6801 8.0132
OAW28 CTRP2 6.2054 11.7251 2.6153 8.1493
JHOS-2 CTRP2 6.3509 12.6504 2.2677 9.3145
OAW42 CTRP2; CTRP1 6.6434 7.8819 4.6515 0.2191
OC 314 CTRP2 6.7874 13.725 2.057 9.4618
OV7 CTRP2; CTRP1 6.8713 14.2283 1.8828 10.0766
JHOC-5 CTRP2; CTRP1 7.4487 8.917 4.5864 0.1228
OVCAR-4 CTRP2; CTRP1 8.2806 15.5344 2.2007 6.9398
COV644 CTRP2; CTRP1 8.4072 17.2804 1.4626 9.4516
RMUG-S CTRP1 8.6302 18.7279 0.9225 18.5625
⏷ Show the Full List of 43 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 5.8062 8.3649 3.9681 3.2479
Aska-SS CTRP2 6.602 8.5993 4.3359 1.0036
KYM-1 CTRP2 1.5974 4.777 1.3521 23.8131
TE 617.T CTRP2 1.6806 3.9436 1.6048 22.6673
Rh18 CTRP2 2.3948 4.9078 2.1889 18.3686
HT-1080 CTRP2; CTRP1 2.5217 4.2915 2.4554 17.112
Rh41 CTRP2 2.8006 3.8853 2.7903 14.9831
SK-LMS-1 CTRP2 3.1504 5.0704 2.9703 13.2487
G-401 CTRP1 3.2109 5.6935 2.8391 29.1033
TTC-709 CTRP2 3.2861 7.0152 2.3758 15.1434
RKN CTRP2; CTRP1 3.5659 7.4504 2.4692 14.1379
Hs 729.T CTRP2 3.7531 7.5413 2.6055 13.046
G-402 CTRP2 3.8799 7.4442 2.7754 12.0493
A-204 CTRP2 4.1117 8.1247 2.6715 11.9277
BT-16 CTRP2 4.1735 5.6572 3.8773 6.8962
MES-SA CTRP2 4.1746 4.9943 4.1084 6.0249
SW982 CTRP2 4.8512 8.7217 3.0424 8.7932
TE 441.T CTRP2 5.1682 6.2335 4.5496 1.8526
BT-12 CTRP2 5.1969 6.1668 4.6047 1.574
SK-UT-1 CTRP2 5.2082 12.1144 1.645 13.809
GCT CTRP2 5.4278 10.9637 2.3979 10.3687
Tm87-16 CTRP2 6.668 8.5808 4.3761 0.8352
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 6.06 9.8886 3.4076 5.1484
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SYO-1 CTRP2 7.0864 8.8713 4.4491 0.4213
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H CTRP2; CTRP1 0.5936 3.4871 0.5078 30.0071
NCI-H28 CTRP2; CTRP1 2.7767 6.1324 2.2105 17.2448
ACC-MESO-1 CTRP2 3.2531 4.6868 3.1742 12.2046
NCI-H2452 CTRP2 3.6034 7.7808 2.3462 14.4581
NCI-H2052 CTRP2; CTRP1 3.7931 6.3955 3.1738 10.7518
MPP 89 CTRP2 4.8796 8.4821 3.1864 8.1326
IST-Mes1 CTRP2 4.9719 13.0601 0.9759 16.8213
JL-1 CTRP2 8.0541 13.86 2.8205 4.8701
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PaCa-3 CTRP2; CTRP1 1.4641 3.725 1.4033 24.1311
22Rv1 CTRP2 4.4729 8.0447 3.0449 9.5752
NCI-H660 CTRP2 5.7592 25.2063 -4.4472 29.3211
DU145 CTRP2 8.4898 15.748 2.2186 6.5614
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 2.0523 7.4855 0.8957 24.1057
A-253 CTRP2 6.5156 11.4858 2.952 6.3178
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MKN1 CTRP2 1.7678 4.2923 1.6423 22.2583
Hs 746.T CTRP2 2.0539 4.6713 1.8746 20.5425
GSS CTRP2 2.2397 4.2083 2.1647 18.9403
LMSU CTRP2 2.3118 4.282 2.2305 18.482
ECC12 CTRP2 2.3528 3.0145 2.3528 17.9317
SNU-719 CTRP2 2.7972 6.4729 2.0946 17.5499
ECC10 CTRP2 3.194 5.5043 2.883 13.44
GSU CTRP2 3.2565 3.9313 3.2546 11.9175
SH-10-TC CTRP2; CTRP1 3.4962 6.3558 2.8829 12.6799
SNU-668 CTRP2 3.5851 8.2969 2.0851 15.5496
SNU-5 CTRP2 3.9481 6.7458 3.1679 10.2943
NUGC-4 CTRP2; CTRP1 4.0526 6.3127 3.4758 8.8826
23132/87 CTRP2 4.1257 5.7297 3.7973 7.3365
MKN74 CTRP2; CTRP1 4.2945 7.726 3.0448 10.0557
SNU-620 CTRP2 4.44 8.3957 2.8418 10.491
SNU-216 CTRP2 5.0138 9.2453 2.9184 8.9903
NCI-N87 CTRP2 5.1255 7.6258 3.8206 4.9894
AGS CTRP2; CTRP1 5.1527 7.0188 4.156 3.6146
NUGC-3 CTRP2 5.7243 9.7354 2.4832 4.4419
MKN7 CTRP2; CTRP1 5.7952 8.5675 3.8739 3.723
MKN45 CTRP2 6.3541 7.59 4.6278 0.3484
SNU-601 CTRP2 6.5131 9.4585 3.908 2.5757
KE-39 CTRP2 6.642 12.3069 2.643 7.3681
KATO III CTRP2 6.9715 8.7485 4.4474 0.4756
HGC-27 CTRP2 6.9968 10.7524 3.6066 3.1532
Fu97 CTRP2; CTRP1 7.0471 13.7653 2.2306 8.4686
SNG-M CTRP2; CTRP1 1.8931 4.2042 1.7942 21.4071
SNU-1077 CTRP2 2.4229 4.6115 2.289 17.926
SNU-685 CTRP2 3.5225 6.3966 2.8876 12.5076
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
B-CPAP CTRP2 -0.1346 0.5987 -0.1346 34.5032
8505C CTRP2 1.0935 4.6879 0.8246 27.2412
FTC-238 CTRP2 1.1014 2.8524 1.0902 26.3063
8305C CTRP2 2.3691 6.955 1.4476 21.1912
FTC-133 CTRP2 2.8599 5.1712 2.6246 15.381
CGTH-W-1 CTRP2 3.1909 4.8956 3.0602 12.8018
SW579 CTRP2 3.9015 6.9199 3.0413 10.9203
ML-1 [Human leukemia] CTRP2 4.13 5.6145 3.8485 7.1264
CAL-62 CTRP2 4.2706 8.0457 2.8585 10.7967
TT CTRP2 4.8326 7.6269 3.5727 6.6075
BHT-101 CTRP2 4.9667 10.0656 2.4687 10.9526
TT2609-C02 CTRP2 5.7156 11.9825 2.1176 10.9886
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-46 CTRP2 1.3054 5.9248 0.6936 27.03
SNU-1214 CTRP2 1.4844 5.278 1.093 25.0795
YD-8 CTRP2 1.7213 6.5986 0.9002 25.0493
SCC-25 CTRP2 2.1735 5.2445 1.8545 20.2478
HSC-3 CTRP2 2.375 4.9011 2.1691 18.5003
HSC-2 CTRP2; CTRP1 2.4435 4.1933 2.3859 17.6024
SNU-1041 CTRP2 2.8338 7.8296 1.553 19.5325
SNU-899 CTRP2 2.9847 6.3336 2.3487 16.0577
SNU-1076 CTRP2 3.9608 6.1482 3.4482 9.144
SCC-4 CTRP2 4.0677 7.6997 2.8352 11.3582
YD-10B CTRP2 4.0854 6.1233 3.5872 8.2688
BHY CTRP2 4.2333 7.3014 3.1849 9.5365
PE/CA-PJ49 CTRP2 4.5548 5.7532 4.2297 4.5037
BICR 56 CTRP2 4.9484 9.2428 2.8646 9.343
FaDu CTRP2 5.1188 6.1969 4.5289 2.0273
SCC-9 CTRP2; CTRP1 5.2014 8.7815 3.3149 7.0522
PE/CA-PJ41 (clone D2) CTRP2 5.2104 8.4705 3.4676 6.3138
SNU-1066 CTRP2 5.2486 8.448 3.5096 6.0674
Detroit 562 CTRP2 5.299 7.8741 3.8357 4.6101
HSC-4 CTRP2 5.4204 11.6863 2.0314 11.8715
CAL-33 CTRP2 6.4327 8.7255 4.1915 1.6307
BICR 16 CTRP2 6.6832 8.949 4.2294 1.2759
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
5637 CTRP2; CTRP1 -0.1862 4.1172 -0.4384 35.6878
SW1710 CTRP2 1.879 5.712 1.387 22.8293
JMSU-1 CTRP2 2.3703 4.3682 2.279 18.1271
RT-112 CTRP2 2.8696 3.8291 2.8636 14.5088
HT-1376 CTRP2; CTRP1 2.9052 5.2102 2.6654 15.1778
TCCSUP CTRP2 3.1155 5.9116 2.6521 14.5335
KU-19-19 CTRP2 3.9206 5.8848 3.518 8.9779
253J CTRP2 3.9421 4.9096 3.8753 7.5746
UM-UC-3 CTRP2; CTRP1 4.1642 7.8234 2.8749 11.0535
KMBC-2 CTRP2; CTRP1 4.551 7.971 3.1606 9.0074
RT-4 CTRP2; CTRP1 4.907 10.6072 2.1571 12.4255
SCaBER CTRP2 4.9574 5.9734 4.5055 2.4389
639V CTRP2 5.0961 6.6764 4.2711 3.1518
UM-UC-1 CTRP2 5.2052 11.2966 2.0513 12.1966
253J-BV CTRP2 5.2135 7.2483 4.08 3.739
CAL-29 CTRP2 5.2442 6.9611 4.2471 2.9851
BC-3C CTRP2 5.3482 6.7128 4.4478 1.9786
VM-CUB-1 CTRP2 5.7556 9.8598 3.2007 6.4778
J82 CTRP2 5.9856 14.7118 0.9709 14.9173
T24 CTRP2 6.0489 10.8803 2.9154 7.1767
HT-1197 CTRP2 6.49 12.7353 2.327 8.8583
U-BLC1 CTRP2 7.6563 14.8523 2.1091 8.0135
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HeLa CTRP2 4.1206 4.8304 3.7432 1.4787

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Simvastatin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Simvastatin and Mipomersen. Hyper-lipoproteinaemia [5C80] [25]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Simvastatin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [26]
BMS-201038 DMQTAGO Major Decreased metabolism of Simvastatin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [27]
Coadministration of a Drug Treating the Disease Different from Simvastatin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Simvastatin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [28]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Simvastatin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [29]
Midostaurin DMI6E0R Moderate Decreased clearance of Simvastatin due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [30]
Arn-509 DMT81LZ Moderate Increased metabolism of Simvastatin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [30]
Emapalumab DMZG5WL Moderate Altered metabolism of Simvastatin due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [30]
Siltuximab DMGEATB Moderate Altered metabolism of Simvastatin due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [30]
Dronedarone DMA8FS5 Major Decreased clearance of Simvastatin due to the transporter inhibition by Dronedarone. Angina pectoris [BA40] [31]
Nifedipine DMSVOZT Moderate Decreased metabolism of Simvastatin caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [32]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Simvastatin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [33]
Posaconazole DMUL5EW Major Decreased metabolism of Simvastatin caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [28]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Simvastatin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [34]
Clarithromycin DM4M1SG Major Decreased metabolism of Simvastatin caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Troleandomycin DMUZNIG Major Decreased metabolism of Simvastatin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Telithromycin DMZ4P3A Major Decreased metabolism of Simvastatin caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Ag-221 DMS0ZBI Moderate Decreased clearance of Simvastatin due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [28]
Erdafitinib DMI782S Moderate Increased metabolism of Simvastatin caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [37]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Simvastatin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [38]
Talazoparib DM1KS78 Moderate Decreased clearance of Simvastatin due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [39]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Simvastatin caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Tucatinib DMBESUA Major Decreased metabolism of Simvastatin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
Palbociclib DMD7L94 Moderate Decreased metabolism of Simvastatin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Anisindione DM2C48U Minor Increased plasma concentration of Simvastatin and Anisindione due to competitive binding of plasma proteins. Coagulation defect [3B10] [41]
Mifepristone DMGZQEF Major Decreased metabolism of Simvastatin caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [42]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Simvastatin caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [32]
Lumacaftor DMCLWDJ Major Increased metabolism of Simvastatin caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [28]
Ivacaftor DMZC1HS Moderate Decreased clearance of Simvastatin due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [43]
MK-8228 DMOB58Q Major Decreased clearance of Simvastatin due to the transporter inhibition by MK-8228. Cytomegaloviral disease [1D82] [44]
Aprepitant DM053KT Moderate Decreased metabolism of Simvastatin caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [32]
Nefazodone DM4ZS8M Major Decreased metabolism of Simvastatin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [40]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Simvastatin caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Stiripentol DMMSDOY Moderate Decreased metabolism of Simvastatin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [46]
Rufinamide DMWE60C Moderate Increased metabolism of Simvastatin caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Simvastatin caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Simvastatin and Cannabidiol. Epileptic encephalopathy [8A62] [30]
Itraconazole DMCR1MV Major Decreased metabolism of Simvastatin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [26]
Miconazole DMPMYE8 Moderate Decreased metabolism of Simvastatin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [30]
Ketoconazole DMPZI3Q Major Decreased metabolism of Simvastatin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [47]
Boceprevir DMBSHMF Major Decreased metabolism of Simvastatin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Simeprevir DMLUA9D Moderate Decreased clearance of Simvastatin due to the transporter inhibition by Simeprevir. Hepatitis virus infection [1E50-1E51] [48]
Telaprevir DMMRV29 Major Decreased metabolism of Simvastatin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Rifampin DMA8J1G Major Increased metabolism of Simvastatin caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [49]
Rifapentine DMCHV4I Moderate Increased metabolism of Simvastatin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [50]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Simvastatin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [51]
Delavirdine DM3NF5G Major Decreased metabolism of Simvastatin caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [52]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Simvastatin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [53]
Fostemsavir DM50ILT Moderate Decreased clearance of Simvastatin due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [54]
Cobicistat DM6L4H2 Major Decreased metabolism of Simvastatin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [40]
Tipranavir DM8HJX6 Major Decreased metabolism of Simvastatin caused by Tipranavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [53]
Saquinavir DMG814N Major Decreased metabolism of Simvastatin caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [53]
Etravirine DMGV8QU Moderate Increased metabolism of Simvastatin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [55]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Simvastatin and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [56]
Amprenavir DMLMXE0 Major Decreased metabolism of Simvastatin caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [53]
Darunavir DMN3GCH Major Decreased metabolism of Simvastatin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [53]
Atazanavir DMSYRBX Major Decreased metabolism of Simvastatin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [53]
Levamlodipine DM92S6N Major Decreased metabolism of Simvastatin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [57]
Conivaptan DM1V329 Major Decreased metabolism of Simvastatin caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [35]
Lesinurad DMUR64T Moderate Increased metabolism of Simvastatin caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [58]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Simvastatin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [32]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Simvastatin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [32]
Crizotinib DM4F29C Moderate Decreased metabolism of Simvastatin caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [32]
Brigatinib DM7W94S Moderate Increased metabolism of Simvastatin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [59]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Simvastatin and Porfimer Sodium. Lung cancer [2C25] [60]
Ceritinib DMB920Z Major Decreased metabolism of Simvastatin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [40]
PF-06463922 DMKM7EW Moderate Increased metabolism of Simvastatin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [61]
Osimertinib DMRJLAT Moderate Increased metabolism of Simvastatin caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [30]
Selpercatinib DMZR15V Moderate Decreased metabolism of Simvastatin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [32]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Simvastatin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [62]
Idelalisib DM602WT Major Decreased metabolism of Simvastatin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [40]
IPI-145 DMWA24P Moderate Decreased metabolism of Simvastatin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [32]
Arry-162 DM1P6FR Moderate Decreased clearance of Simvastatin due to the transporter inhibition by Arry-162. Melanoma [2C30] [28]
LGX818 DMNQXV8 Moderate Increased metabolism of Simvastatin caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [63]
Dabrafenib DMX6OE3 Moderate Decreased clearance of Simvastatin due to the transporter inhibition by Dabrafenib. Melanoma [2C30] [28]
Danazol DML8KTN Major Decreased metabolism of Simvastatin caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [34]
Exjade DMHPRWG Moderate Decreased metabolism of Simvastatin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [64]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Simvastatin and Thalidomide. Multiple myeloma [2A83] [56]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Simvastatin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [32]
Dasatinib DMJV2EK Moderate Decreased metabolism of Simvastatin caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [32]
Modafinil DMYILBE Moderate Increased metabolism of Simvastatin caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [28]
Netupitant DMEKAYI Moderate Decreased metabolism of Simvastatin caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [34]
Entrectinib DMMPTLH Moderate Decreased metabolism of Simvastatin caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [32]
Olaparib DM8QB1D Moderate Decreased metabolism of Simvastatin caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [28]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Simvastatin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [32]
Abametapir DM2RX0I Moderate Decreased metabolism of Simvastatin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [65]
Esomeprazole DM7BN0X Moderate Increased plasma concentrations of Simvastatin and Esomeprazole due to competitive inhibition of the same metabolic pathway. Peptic ulcer [DA61] [49]
Lefamulin DME6G97 Moderate Decreased metabolism of Simvastatin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [66]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Simvastatin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [67]
Enzalutamide DMGL19D Moderate Increased metabolism of Simvastatin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [68]
Darolutamide DMV7YFT Moderate Decreased clearance of Simvastatin due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [30]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Simvastatin caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [32]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Simvastatin due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [30]
Ixekizumab DMXW92T Moderate Altered metabolism of Simvastatin due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [30]
Tocilizumab DM7J6OR Moderate Altered metabolism of Simvastatin due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [30]
Canakinumab DM8HLO5 Moderate Altered metabolism of Simvastatin due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [30]
Rilonacept DMGLUQS Moderate Altered metabolism of Simvastatin due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [30]
Sarilumab DMOGNXY Moderate Altered metabolism of Simvastatin due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [30]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Simvastatin and Leflunomide. Rheumatoid arthritis [FA20] [26]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Simvastatin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [32]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Simvastatin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [30]
Larotrectinib DM26CQR Moderate Decreased metabolism of Simvastatin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [32]
Armodafinil DMGB035 Moderate Increased metabolism of Simvastatin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [28]
LEE011 DMMX75K Moderate Decreased metabolism of Simvastatin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [32]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Simvastatin and Naltrexone. Substance abuse [6C40] [69]
Warfarin DMJYCVW Minor Increased plasma concentration of Simvastatin and Warfarin due to competitive binding of plasma proteins. Supraventricular tachyarrhythmia [BC81] [41]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Simvastatin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [70]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Simvastatin due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [71]
Brilinta DMBR01X Moderate Decreased metabolism of Simvastatin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [30]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Simvastatin and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [72]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Simvastatin and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [72]
Albiglutide DM1JEGF Minor Altered absorption of Simvastatin due to GI dynamics variation caused by Albiglutide. Type 2 diabetes mellitus [5A11] [46]
Dapagliflozin DM28UJG Minor Increased plasma concentrations of Simvastatin and Dapagliflozin due to competitive inhibition of the same metabolic pathway. Type 2 diabetes mellitus [5A11] [73]
Amiodarone DMUTEX3 Major Decreased metabolism of Simvastatin caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [74]
⏷ Show the Full List of 111 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Calcium ascorbate anhydrous E00582 54740489 Antioxidant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Ascorbic acid E00579 54670067 Acidulant; Antioxidant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Carmellose sodium E00625 Not Available Disintegrant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
⏷ Show the Full List of 23 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Simvastatin 80 mg tablet 80 mg Oral Tablet Oral
Simvastatin 10 mg tablet 10 mg Oral Tablet Oral
Simvastatin 40 mg tablet 40 mg Oral Tablet Oral
Simvastatin 20 mg tablet 20 mg Oral Tablet Oral
Simvastatin 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Simvastatin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2955).
3 Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Pharmazie. 2013 Feb;68(2):124-8.
4 BDDCS applied to over 900 drugs
5 Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, Yokoi T: Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008 Jan 29;51(4):435-43. doi: 10.1016/j.jacc.2007.05.057.
9 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
10 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
11 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
12 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
13 A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8.
14 Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs. 2004;4(4):247-55.
15 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
16 In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997 Oct;25(10):1191-9.
17 Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81.
18 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
19 Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008 Jul 22;118(4):355-62. doi: 10.1161/CIRCULATIONAHA.108.773267. Epub 2008 Jun 16.
20 Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007 Sep;36(3):329-35. doi: 10.1002/mus.20871.
21 Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. J Cell Mol Med. 2018 Feb;22(2):873-882. doi: 10.1111/jcmm.13373. Epub 2017 Oct 3.
22 Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Hum Reprod. 2007 Apr;22(4):1161-7. doi: 10.1093/humrep/del464. Epub 2006 Dec 11.
23 Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
24 In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
25 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
26 Canadian Pharmacists Association.
27 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
28 Cerner Multum, Inc. "Australian Product Information.".
29 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
30 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
31 Holtzman CW, Wiggins BS, Spinler SA "Role of P-glycoprotein in statin drug interactions." Pharmacotherapy 26 (2006): 1601-7. [PMID: 17064205]
32 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
33 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
34 Andreou ER, Ledger S "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis." Can J Clin Pharmacol 10 (2003): 172-4. [PMID: 14712320]
35 Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
36 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
37 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
38 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
39 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
40 Alderman CP "Possible interaction between nefazodone and pravastatin." Ann Pharmacother 33 (1999): 871. [PMID: 10466919]
41 Gaw A, Wosornu D "Simvastatin during warfarin therapy in hyperlipoproteinaemia." Lancet 340 (1992): 979-80. [PMID: 1357387]
42 He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
43 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
44 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
45 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
46 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
47 Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20. [PMID: 17368833]
48 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
49 Bogman K, Peyer AK, Torok M, Kusters E, Drewe J "HMG-CoA reductase inhibitors and P-glycoprotein modulation." Br J Pharmacol 132 (2001): 1183-92. [PMID: 11250868]
50 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
51 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
52 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
53 Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
54 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
55 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
56 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
57 Product Information. Zocor (simvastatin). Merck & Co, Inc, West Point, PA.
58 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
59 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
60 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
61 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
62 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
63 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
64 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
65 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
66 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
67 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
68 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
69 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
70 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
71 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
72 Barshes NR, Goodpastor SE, Goss JA "Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient." Transplantation 76 (2003): 1649-50. [PMID: 14702546]
73 Product Information. Farxiga (dapagliflozin). Bristol-Myers Squibb, Princeton, NJ.
74 Chouhan UM, Chakrabarti S, Millward LJ "Simvastatin interaction with clarithromycin and amiodarone causing myositis." Ann Pharmacother 39 (2005): 1760-1. [PMID: 16159992]